Zoryl-M is available in 4 strenths:
Glimepiride 1 mg + Metformin Hydrochloride 500 mg
Glimepiride 2 mg + Metformin Hydrochloride 500 mg
Glimepiride 3 mg + Metformin Hydrochloride 500 mg
Glimepiride 4 mg + Metformin Hydrochloride 500 mg
The combination Metformin + Sulfonylurea (Glimipiride belongs to class Sulfonylurea) is recommended by Global Bodies as the First line of Choice in the management of Type 2 Diabetes.
Glimipiride functions by stimulating the insulin release from beta cells (beta cells are present in Pancreas) and inhibits gluconeogenesis (generation of glucose)
at hepatic (Liver) cells. It also increases insulin sensitivity at peripheral target sites.
Metformin decreases hepatic gluconeogenesis, decreases intestinal absorption of glucose and improves insulin sensitivity (increases peripheral glucose uptake and utilisation).
Intas ranks 11th in the Indian pharmaceutical market. It is a leading, global pharmaceutical formulation development, manufacturing and marketing company headquartered in India. Intas operates in more than 80 countries globally. The company is known for its range of products in Oncology and other hospital based therapeutic segments in the EU and US.